drugset / Trial / NCT00155389

Community-based Helicobacter Pylori Eradication

NCT00155389

Phase 4 Unknown 5000 enrolled National Taiwan University Hospital
NaSingle-groupOpen-labelTreatment

Summary

Based on a universal eradication of H. pylori in an offshore island (Matsu) with a high prevalence of gastric cancer as well as premalignant gastric lesion, we first examined the infection rate of H. pylori. Secondly, we evaluated the efficacy of clarithromycin-based triple therapy with a levofloxacin-based rescue treatment. And thirdly, we tested the hypothesis that whether the cure of H. pylori can reverse the premalignant gastric lesion. Fourth, we determine the cost-effectiveness of this intervention. The gene-environment interaction will be addressed regarding gastric cancer carcinogenesis. Finally, the incident rate of gastric cancer would be followed in this cohort.

Timeline

Start
2004-01
Primary completion
2015-12
Completion
2015-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified 1 g
Comparator Clarithromycin Small molecule 500 mg
Comparator Esomeprazole Small molecule 40 mg
Comparator Levofloxacin Small molecule 500 mg